Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 1 · 50%High 0 · 0%

Infliximab 5 mg/kg vs infliximab 20 mg/kg

Clinical response as defined by the studies week 4 · Patients with active Crohn's disease

It is very uncertain whether infliximab 5 mg/kg changes clinical response as defined by the studies week 4 compared with infliximab 20 mg/kg (very low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1.27 [0.91, 1.76]
1 study · 55 participants
Very low

Infliximab 5 mg/kg and purine analogues vs purine analogues

Clinical response as defined by the studies at week 26 · Patients with active Crohn's disease

Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1.64 [1.31, 2.05]
2 studies · 355 participants
Moderate